Outlook Therapeutics, Inc. - 8-K Filing
Outlook Therapeutics reported a net loss attributable to common stockholders of $4.5 million ($0.05 per share) for the second fiscal quarter ended March 31, 2026, compared to $46.4 million ($1.50 per share) in the same period last year. The company also announced a formal dispute resolution meeting with the FDA regarding its Complete Response Letter (CRL) for ONS-5010 and expects a decision by May 2026. Additionally, it expanded LYTENAVA™ distribution into Switzerland via a Commercial Distribution Agreement with Mediconsult AG. (Items: 2.02 Results of Operations and Financial Condition On May 15, 2026, Outlook Therapeutics, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $OTLK